Patrick J. Flynn

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 5 papers. Top paper: “A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11”.

A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-2137

N/A

0.330DataRank · unranked

8 citations

Opeyemi A. Jegede, Victor T. Chang, Todd C. Skaar, Jeffrey L. Berenberg, Ranveer Nand +15 more

Prospective validation of genetic predictors of aromatase inhibitor-associated musculoskeletal symptoms (AIMSS) in a racially diverse cohort: Results from ECOG-ACRIN E1Z11.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.12003

N/A

0.165DataRank · unranked

2 citations

Opeyemi A. Jegede, Victor T. Chang, Todd C. Skaar, Jeffrey L. Berenberg, Ranveer Nand +15 more

CODEL: phase III study of RT, RT + TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design

Neuro-Oncology(2020)10.1093/neuonc/noaa168

N/A

0DataRank · unranked

116 citations

Karla V. Ballman, Martin J. van den Bent, Caterina Giannini, Evanthia Galanis, Paul D. Brown +18 more

Predictive value of baseline patient-rated treatment bother for early anastrozole discontinuation in a racially diverse cohort: Results from ECOG-ACRIN E1Z11.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.12094

N/A

0DataRank · unranked

0 citations

John Devin Peipert, Vered Stearns, Victor T. Chang, Opeyemi A. Jegede, Edward H. Ip +15 more

Intergroup randomized phase III study of adjuvant FOLFIRI, FOLFOX, or 5-FU/leucovorin for stage II/III rectal cancer: ECOG-ACRIN E3201

The Oncologist(2025)10.1093/oncolo/oyaf416

N/A

0DataRank · unranked

0 citations

Fengmin Zhao, Neal J. Meropol, Bruce J. Giantonio, Robert B. Diasio, Patrick J. Flynn +14 more